ARUP's Laboratory Test Directory

Beta-2-Adrenergic Receptor (ADBR2) Haplotyping : 0051288
[ image for: Additional Technical Information]
Additional Technical Information
  


Mnemonic: ADRB2 HAP

Ordering Recommendation: Predict asthma severity and long-term response to beta agonists.
Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu
Reported: 2-7 days
Specimen Required: Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature: Refrigerated.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval:
By report
Interpretive Data: Background Information for Beta-2-Adrenergic Receptor (ADRB2) Haplotyping:
Characteristics:
The ADRB2 gene encodes for the beta-2-adrenergic receptors expressed on many cell types including cells of the airways, the vascular and immune systems, and fat cells. Binding and release of epinephrine and norepinephrine, the natural ligands on the receptor, regulates cardiac, pulmonary, vascular, immunologic, and metabolic functions. The beta-2-adrenergic receptors are the targets of beta-agonists drugs. ADRB2 appears to be one of the multiple genetic players in asthma, vascular disease, obesity and drug response.
Genetics:
At least twelve haplotypes of the ADRB2 gene have been described using 13 polymorphic sites. The three haplotypes (Gly16-Glu27, Arg16-Gln27 and Gly16-Gln27) are the most common. Arg16 and Gln27 are in strong linkage disequilibrium. Arg16 has been found associated with Glu27 in less than 0.5 percent of chromosomes.
Mutations Tested:
Arg16Gly (c.46A>G), Gln27Glu (c.79C>G) and the three main haplotypes Gly16-Glu27, Arg16-Gln27, and Gly16-Gln27.
Methodology:
PCR and fluorescence analysis by haplotyping hybridization probes. In addition to genotyping each mutation tested, this test directly establishes the haplotype (whether or not the two mutations are found on the same or different chromosomes).
Limitations:
Mutations and haplotypes situated outside of the studied area of the gene are not analyzed. Other and non-described mutations and haplotypes can be revealed by the assay. Medical significance of the polymorphisms and their haplotypes in the different diseases (asthma, obesity, hypertension, and drug response) are continually being investigated.
Analytical Sensitivity:
The assay determines the haplotypes of approximately 99 percent of chromosomes.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

Refer to Statement C under Testing Information at http://www.aruplab.com.
CPT Code(s): 81401